Analyst Ratings February 11, 2026

Barclays Lowers Robinhood Target to $124 After Tepid Q4; Overweight Rating Stands

Analyst trims price objective as take rates and securities lending soften, while account momentum and expense control offer mixed signals

By Leila Farooq HOOD
Barclays Lowers Robinhood Target to $124 After Tepid Q4; Overweight Rating Stands
HOOD

Barclays cut its price target on Robinhood Markets to $124 from $159 but retained an Overweight rating following weaker-than-expected fourth-quarter results. Revenue pressures came from lower take rates in options and cryptocurrency trading and reduced securities lending, even as the company remained profitable and posted strong year-over-year revenue growth. Net new account trends slowed in December before modestly improving in January, with February showing signs of stronger new-account activity.

Key Points

  • Barclays cut Robinhood's price target to $124 from $159 but maintained an Overweight rating.
  • Weakness in transaction revenues from lower take rates in options and crypto, along with reduced securities lending, drove the softer Q4 results.
  • Net new accounts decelerated in December, improved modestly in January, and February began stronger; trading volumes rose month-to-month but market-share commentary was inconclusive.

Barclays has reduced its price target for Robinhood Markets to $124.00 from $159.00 while keeping an Overweight rating on the shares. The stock is trading at $76.40 and has experienced notable volatility - down 24.31% year-to-date but up 60.48% over the past 12 months. According to InvestingPro analysis cited with the report, the stock is trading above its Fair Value.

The bank's revision follows Robinhood's softer-than-anticipated fourth-quarter performance. Barclays pointed to several revenue pressures: lower take rates in options and cryptocurrency trading that weighed on transaction revenues, and reduced securities lending that detracted from net interest income.

Despite these headwinds, the company remained profitable in the period. Robinhood reported a price-to-earnings ratio of 36.05 and delivered strong top-line momentum, with revenue growing 74.58% over the last twelve months.

Barclays identified net new accounts (NNAs) as the most consequential datapoint in the earnings release. NNAs decelerated in December, the bank said, then improved modestly in January. February, Barclays added, appeared to start on firmer footing, particularly with respect to new account growth.

The bank also observed that trading volumes increased month-over-month across all categories in February. However, commentary on market share was less definitive - Barclays noted that exchange volumes broadly rose during the same period, making it harder to isolate changes in Robinhood's share of trading activity.

On the cost side, Barclays highlighted that operating expenses came in better than expected for the quarter. The firm also noted that Robinhood's fiscal 2026 guidance was consistent with consensus estimates and that the company continues to pursue what Barclays described as an "ambitious growth roadmap" for 2026.

Robinhood's fourth-quarter 2025 reported results painted a mixed picture. The broker-dealer posted earnings per share of $0.66, topping the consensus estimate of $0.64 and Citizens' internal estimate of $0.65. Revenue, however, missed expectations: the company recorded $1.28 billion versus a projected $1.34 billion.

Analyst reactions to the earnings have varied. Piper Sandler cut its price target to $135 while maintaining an Overweight rating in response to the revenue shortfall. Compass Point trimmed its target to $127 after noting a 9% miss on EBITDA, which it attributed to lower securities lending income and reduced take rates in crypto and options trading. Needham lowered its price target to $100, pointing to especially strong results in prediction markets, where volumes reached record levels. By contrast, Citizens left its Market Outperform rating intact and stands by a $180 price target following the report.

Together, the recent analyst moves underscore divergent views among sell-side firms on Robinhood's near-term revenue drivers and longer-term growth prospects. While some firms trimmed targets in response to the revenue and EBITDA misses, others highlighted profitable operations and areas of growth such as prediction markets and improving account trends.


Key takeaways

  • Barclays lowered its price target to $124 from $159 but kept an Overweight rating.
  • Q4 results were pressured by lower take rates in options and crypto and reduced securities lending, though the company remains profitable with strong revenue growth.
  • Net new account trends slowed in December, improved modestly in January, and appeared stronger in early February; trading volumes rose month-over-month but market share commentary was unclear.

Risks and uncertainties

  • Revenue sensitivity to take rates in options and cryptocurrency trading - impacts brokerage and fintech revenue streams.
  • Volatility in securities lending income - affects net interest income and profitability for broker-dealers.
  • Unclear market-share trajectory amid broader exchange volume increases - complicates competitive assessment in the trading and exchange ecosystem.

Risks

  • Revenue exposure to lower take rates in options and cryptocurrency trading - impacts fintech and brokerage revenue streams.
  • Reduced securities lending income can depress net interest income and EBITDA - a risk for broker-dealer financials.
  • Ambiguity around market share as exchange volumes increase broadly - creates uncertainty for competitive positioning in trading markets.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026